UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Xencor, Inc. $XNCR

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 214.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 382,094 shares of the biopharmaceutical company’s stock after acquiring an additional 260,752 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Xencor were worth $6,152,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP purchased a new position in shares of Xencor during the second quarter valued at approximately $55,000. Tower Research Capital LLC TRC lifted its stake in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in shares of Xencor during the 2nd quarter worth approximately $79,000. Norges Bank purchased a new position in Xencor during the 4th quarter valued at $175,000. Finally, Prelude Capital Management LLC purchased a new position in Xencor during the 3rd quarter valued at $139,000.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wedbush increased their target price on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a report on Thursday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Xencor Price Performance

XNCR stock opened at $25.33 on Wednesday. Xencor, Inc. has a 1-year low of $8.25 and a 1-year high of $30.61. The business has a 50-day moving average price of $21.47 and a 200 day moving average price of $15.53. The company has a market capitalization of $1.88 billion, a P/E ratio of -11.67 and a beta of 0.88.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.41) EPS. On average, analysts anticipate that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.